GlassScriptPhysician profile
Marion Colas-Lacombe
NPI 1346282670
$4,097.58
in general payments reported to CMS, 2019-2025
34 companies · $564 in 2025
The $564 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $498 · 2021: $872 · 2022: $530 · 2023: $670 · 2024: $678 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.27 | 2019-2023 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $334.82 | 2020-2025 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $322.87 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $293.06 | 2021-2025 | |
| Astellas Pharma US INC | $282.70 | 2023-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $200.73 | 2019-2022 | |
| Coopersurgical, INC. | $189.89 | 2020-2024 | Paragard T 380a, Paragard T 380a, Endosee |
| Sumitomo Pharma America, INC. | $189.82 | 2023-2025 | Myfembree, Gemtesa |
| Evofem Biosciences, INC. | $154.58 | 2021-2025 | Phexxi, Solosec, Phexx |
| Millicent US INC | $153.42 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Avion Pharmaceuticals | $146.70 | 2020-2021 | |
| Cook Medical LLC | $139.74 | 2024 | Zilver Ptx, Icast Covered Stent System, 6mmx22mmx120cm |
| Shield Therapeutics INC | $130.32 | 2022-2025 | Accrufer |
| Boston Scientific Corporation | $89.74 | 2019 | |
| Aspira Women'S Health INC | $85.52 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $82.28 | 2022 | |
| Lupin INC. | $73.42 | 2020-2021 | |
| Pfizer INC. | $70.67 | 2021-2024 | |
| Zyla Life Sciences, INC. | $65.55 | 2020 | |
| Organon LLC | $59.05 | 2024 | |
| Exact Sciences Corporation | $59.02 | 2023 | Cologuard Collection Kit |
| Myovant Sciences INC. | $57.17 | 2021-2022 | |
| Biosense Webster, INC. | $39.60 | 2025 | Carto 3, Nuvision Ice Catheter |
| Allergan, INC. | $25.20 | 2019-2020 | |
| Kerecis Limited | $21.11 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Mylan Pharmaceuticals INC. | $19.60 | 2021 | |
| Meditrina | $18.59 | 2021 | |
| Exeltis, USA INC. | $17.96 | 2023 | Slynd |
| Mycovia Pharmaceuticals, INC. | $17.24 | 2022 | |
| Roche Diagnostics Corporation | $15.84 | 2019 | |
| Biogen, INC. | $14.35 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $13.61 | 2023 | Twirla |
| Glaxosmithkline, LLC. | $12.95 | 2020 | |
| Merck Sharp & Dohme LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Colas-Lacombe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.